Investment focus
Start with the fit.
Sofinnova Biovelocita II is a life sciences fund managed by Sofinnova Partners that creates and accelerates early-stage biotech start-ups. Based in France with a pan-European reach across Italy, the UK and Denmark, it raised EUR 165 million with backing from pharmaceutical partners including Amgen, Bristol Myers Squibb and Pfizer Ventures.
Reported EIF strategy: Life science and health
EUACC Intelligence
Free preview
EUACC Intelligence
Research Sofinnova Biovelocita II SLP
Explore the record and prepare questions for the fund.
Your side of the introduction
List your startup →